体弱住院老年人肺炎球菌疫苗免疫持久性长期随访
本研究对住院老年人体内23价多糖疫苗与7价结合疫苗免疫原性随机试验的参与者进行6年随访,检测疫苗血清型抗体。215名存活者中136人完成随访,两研究组间死亡与再入院无显著差异,72个月时ELISA与OPA抗体水平组间无显著差异;除OPA抗体对4、6A、6B、9v、19F和23F外,ELISA和OPA抗体仍高于基线。
要点
- 6年随访时两疫苗组ELISA与OPA抗体水平无显著差异。
- 两研究组死亡与再入院无显著差异。
- OPA抗体对部分血清型(4、6A、6B、9v、19F、23F)出现明显衰减。
核心结论
- 接种后6年两研究组ELISA抗体仍较高,但OPA抗体明显衰减,应考虑澳大利亚当前单剂推荐。
- 需进一步研究以指导65岁以上人群肺炎球菌疫苗推荐。
研究设计与样本
- 对住院老年人23vPPV与PCV7免疫原性随机试验参与者的6年随访研究。
- 215名存活试验参与者中136人(63%)完成随访,62人仅接种23vPPV,74人接种PCV7后6个月接种23vPPV。
主要发现
- 两研究组间死亡与再入院无显著差异。
- 接种后72个月,两研究组ELISA与OPA抗体水平无显著差异。
- 除OPA抗体对4、6A、6B、9v、19F和23F外,ELISA和OPA抗体仍高于基线,包括基线免疫不可测者。
临床怎么用
- 对住院体弱老年人接种肺炎球菌疫苗后应关注OPA抗体衰减,尤其对4、6A、6B、9v、19F和23F血清型。
- 当前澳大利亚单剂推荐下,需结合长期免疫衰减数据评估65岁以上人群接种策略。
局限性
- 原文未明确报告随访研究的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on long-term antibody responses to pneumococcal vaccines in the elderly, especially the frail elderly at greatest risk of severe disease, are limited. We followed up participants in a randomised trial of the immunogenicity of 23-valent polysaccharide vaccine (23vPPV) and 7 valent pneumococcal conjugate vaccines (PCV7) in hospitalised older adults. METHODS: We measured antibody to vaccine serotypes by standardised enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic (OPA) assays. A follow up study was conducted six years after vaccination with 23vPPV alone or with PCV7 followed by 23vPPV six months later. RESULTS: Of 215 surviving trial participants, 136 (63%) completed follow up; 62 received 23vPPV and 74 received PCV7 + 23vPPV. There was no significant difference in death and readmission between arms. Antibody levels by ELISA and OPA did not differ significantly between the two study arms at 72 months post-vaccination. ELISA and OPA antibody remained higher than baseline except for OPA antibody to 4, 6A, 6B, 9v, 19F and 23F, including in subjects with undetectable immunity at baseline. DISCUSSION: While ELISA responses in both study arms remained high 6 years post-vaccination, considerable waning was observed by OPA in both study arms, which should be considered given the current single-dose recommendation in Australia. Further research is needed to inform pneumococcal vaccine recommendations in people over the age of 65.
引用
- MacIntyre CR, Ridda I, Trent MJ, et al. Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up. Vaccine. 2019. PMID: 31300288. doi:10.1016/j.vaccine.2019.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。